TNMG
COMMUNICATION SERVICESTNL Mediagene
$1.07+0.13 (+14.27%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TNMG Today?
No stock-specific AI insight has been generated for TNMG yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.80$26.40
$1.07
Fundamentals
Market Cap$3M
P/E Ratio—
EPS$-25.91
Dividend Yield—
Dividend / Share—
ROE-1.6%
Profit Margin-1.7%
Debt / Equity—
Trading
Volume45K
Avg Volume (10D)—
Shares Outstanding2.9M
TNMG News
20 articles- TNL Mediagene Delivers $4M Digital Studio Project with AI, Cutting Review Costs by Over 98%Yahoo Finance·Apr 14, 2026
- TNL Mediagene Announces Leadership Realignment and 2026 Strategic Initiatives to Strengthen Execution, Expand Digital Studio, Content Commerce and AI-Powered Products, and Drive Long-Term Value CreationYahoo Finance·Apr 2, 2026
- TNL Mediagene Announces Exclusive Partnership with Moby to Launch "Moby Japan" on Business Insider Japan PlatformYahoo Finance·Mar 16, 2026
- TNL Mediagene Leverages AWS's Kiro to Accelerate AI-Enabled Operational AdvancementsYahoo Finance·Feb 24, 2026
- TNL Mediagene Announces GIZMART's Debut Project "Keychron Nape Pro" Wins Tom's Hardware's "Best of CES 2026 - Best Mouse" AwardYahoo Finance·Feb 12, 2026
- TNL Mediagene Targets EBITDA Break-Even in 2026 and Positive EBITDA in 2027－Company outlines path driven by technology business growth and cost reductionsYahoo Finance·Feb 6, 2026
- TNL Mediagene Regains Compliance with Nasdaq's Bid Price RuleYahoo Finance·Jan 22, 2026
- TNL Mediagene Announces Conclusion of GIZMART's Debut Project "Keychron Nape Pro," Surpassing ¥300 Million in GMVYahoo Finance·Jan 13, 2026
- TNL Mediagene Supports Japan's Unique, High-Value-Added Fashion IP Development with METI Partnership; Showcase Set for January 2026Yahoo Finance·Jan 7, 2026
- TNL Mediagene Introduces NLWeb Support to Strengthen Its Digital Media as AI-Native Content Infrastructure for the AI-Driven WebYahoo Finance·Jan 6, 2026
- TNL Mediagene Releases H2 and 2025 Corporate Update Presentation to Shareholders, Highlighting Growth of Technology and Digital Studio Business Units, AI Initiatives, Strategic Partnerships and Content Commerce InitiativesYahoo Finance·Dec 30, 2025
- TNL Mediagene Granted Continued Listing by Nasdaq Hearings Panel, Subject to Meeting $1 Bid Price Rule On or Before January 7, 2026Yahoo Finance·Dec 24, 2025
- TNL Mediagene to Launch Agentic Newsroom, an AI-Driven Global Content System, and CiteRadar, an SaaS Analytics Platform for Monitoring AI VisibilityYahoo Finance·Dec 23, 2025
- TNL Mediagene Announces Early Success in AI Content Licensing Revenue Model via TollBit Marketplace Integration and Strategic PartnershipYahoo Finance·Dec 22, 2025
- TNL Mediagene Issues Shareholder Letter Providing H2 and 2025 Corporate UpdateYahoo Finance·Dec 19, 2025
- TNL Mediagene Announces 1-for-20 Share ConsolidationYahoo Finance·Dec 19, 2025
- Sidoti Highlights Improved Financial Flexibility, Shelf Eligibility, Reduced Stock Overhang, and Focus on Operational Execution at TNL MediageneYahoo Finance·Dec 15, 2025
- TNL Mediagene Partners with CMoney, Taiwan's Leading Financial Platform with 10 Million Users, to Redefine the AdTech Landscape in TaiwanYahoo Finance·Dec 11, 2025
- TNL Mediagene Announces Successful INSIDE Future Day 2025 and Releases New AI Agent Industry White PaperYahoo Finance·Dec 9, 2025
- TNL Mediagene Launches LINE Utility Tool "iGood Price-Drop Radar" in Taiwan, Building on ¥200 Million Crowdfunding Success in Japan to Accelerate Media × Tech RoadmapYahoo Finance·Dec 4, 2025
All 20 articles loaded
Price Data
Open$0.95
Previous Close$0.94
Day High$1.09
Day Low$0.95
52 Week High$26.40
52 Week Low$0.80
52-Week Range
$0.80$26.40
$1.07
Fundamentals
Market Cap$3M
P/E Ratio—
EPS$-25.91
Dividend Yield—
Dividend / Share—
ROE-1.6%
Profit Margin-1.7%
Debt / Equity—
Trading
Volume45K
Avg Volume (10D)—
Shares Outstanding2.9M
About TNL Mediagene
TNL Mediagene Ordinary Shares is a forward-thinking biopharmaceutical company dedicated to the development and commercialization of cutting-edge medical therapies aimed at addressing significant unmet medical needs, particularly in the fields of oncology and autoimmune disorders. With a robust pipeline leveraging advanced technologies and strategic partnerships, the company is well-positioned for substantial growth in the dynamic healthcare landscape. TNL Mediagene's unwavering commitment to scientific research and innovative approaches underpins its mission to improve patient outcomes, establishing it as a prominent entity in the biopharmaceutical industry.
COMMUNICATION SERVICESPUBLISHING
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICPUBLISHING
CIK—
Composite FIGI—
Share Class FIGI—